HARARE – Zimbabwe has been chosen as one of ten countries worldwide to introduce lenacapavir, a twice-yearly injectable medicine described as a breakthrough in HIV prevention. “In a large-scale clinical trial more than 99% of people on lenacapavir remained HIV negative. HIV prevalence among adults aged 15 to 49 years declined from 12.69% in 2019 to 10.49% in 2023, reflecting gains in prevention, treatment, and education. Zimbabwe has also expanded access to innovative methods such as the cabotegravir (CAB-LA) injection, another long-acting preventive option available at selected facilities. WHO Zimbabwe representative Dr Desta Tiruneh emphasized the need for sustained investment in prevention, treatment, stigma reduction, and community engagement.